Skip to content

Study · In vitro (cells) · mouse · 2014

11 results

[Effects of thymosin alpha1 on immune effector molecules of mouse].

Li WY, Lu HM, Guo Q, Hu WM, Zhang ZD

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition1 May 2014Cited by 1 (Europe PMC)

PMID24941805 (opens in a new tab)PepBankPUB-24941805
Publisher pageAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In cultured mouse spleen lymphocytes, the OD value was lower with Talpha1 than in the control group after three days.

    In plain wordsIn cells from mouse spleen, the culture OD value was lower with thymosin alpha‑1 than in untreated cells.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseOD value of lymphocyte culture after 3 days
    Study

    mousen: not reported in source

    mouse spleen lymphocyte culture
    Comparator
    Control
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    10 microg/mL · 3 daysAs given in this study (mouse).

    Source sentences

    Summary
    Three days after the culture, OD value in the control group was significantly higher than that in Talppha1 group, CsA group, and CsA+ Talpha1 group (P < 0.05).
    3 context sentences
    Summary · context
    Sixty five BABL/c mice were divided into four groups: CsA group (n=20), Talpha1 group (n= 20), CsA+Talpha1 group (n=20) and control group (n=5).
    Summary · context
    25 mg/mL CsA, 10 microg/mL Talpha1 or 0.25 mg/mL CsA+10 microg/mL Talpha1 in vitro, respectively.
    Summary · context
    Three days later, OD values of each treated lymphocyte culture and several cytokines in the culture were measured.

Studies that did not test the peptide alone10

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice, the combination of CsA and Talpha1 gave lower IL-1alpha than the other groups at 1, 7, 14 and 21 days.

    In plain wordsIn mice, cyclosporin A plus thymosin alpha‑1 gave lower IL-1alpha than the other groups.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-1alpha, combination of CsA and Talpha1
    Study

    mousen: not reported in source

    BALB/c mice
    Comparator
    Other groups
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Compared with other groups, CsA+Talpha1 group had significant lower IL-1alpha, IL-2, IL-6, IL-17, and significant higher IL-10 at 1 d, 7 d, 14 d, 21 d after the treatments (P < 0.05).
    3 context sentences
    Summary · context
    Sixty five BABL/c mice were divided into four groups: CsA group (n=20), Talpha1 group (n= 20), CsA+Talpha1 group (n=20) and control group (n=5).
    Summary · context
    25 mg/mL CsA, 10 microg/mL Talpha1 or 0.25 mg/mL CsA+10 microg/mL Talpha1 in vitro, respectively.
    Summary · context
    Three days later, OD values of each treated lymphocyte culture and several cytokines in the culture were measured.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice, the combination of CsA and Talpha1 gave lower IL-2 than the other groups at 1, 7, 14 and 21 days.

    In plain wordsIn mice, cyclosporin A plus thymosin alpha‑1 gave lower IL-2 than the other groups.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-2, combination of CsA and Talpha1
    Study

    mousen: not reported in source

    BALB/c mice
    Comparator
    Other groups
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Compared with other groups, CsA+Talpha1 group had significant lower IL-1alpha, IL-2, IL-6, IL-17, and significant higher IL-10 at 1 d, 7 d, 14 d, 21 d after the treatments (P < 0.05).
    3 context sentences
    Summary · context
    Sixty five BABL/c mice were divided into four groups: CsA group (n=20), Talpha1 group (n= 20), CsA+Talpha1 group (n=20) and control group (n=5).
    Summary · context
    25 mg/mL CsA, 10 microg/mL Talpha1 or 0.25 mg/mL CsA+10 microg/mL Talpha1 in vitro, respectively.
    Summary · context
    Three days later, OD values of each treated lymphocyte culture and several cytokines in the culture were measured.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice, the combination of CsA and Talpha1 gave lower IL-6 than the other groups at 1, 7, 14 and 21 days.

    In plain wordsIn mice, cyclosporin A plus thymosin alpha‑1 gave lower IL-6 than the other groups.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-6, combination of CsA and Talpha1
    Study

    mousen: not reported in source

    BALB/c mice
    Comparator
    Other groups
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Compared with other groups, CsA+Talpha1 group had significant lower IL-1alpha, IL-2, IL-6, IL-17, and significant higher IL-10 at 1 d, 7 d, 14 d, 21 d after the treatments (P < 0.05).
    3 context sentences
    Summary · context
    Sixty five BABL/c mice were divided into four groups: CsA group (n=20), Talpha1 group (n= 20), CsA+Talpha1 group (n=20) and control group (n=5).
    Summary · context
    25 mg/mL CsA, 10 microg/mL Talpha1 or 0.25 mg/mL CsA+10 microg/mL Talpha1 in vitro, respectively.
    Summary · context
    Three days later, OD values of each treated lymphocyte culture and several cytokines in the culture were measured.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice, the combination of CsA and Talpha1 gave lower IL-17 than the other groups at 1, 7, 14 and 21 days.

    In plain wordsIn mice, cyclosporin A plus thymosin alpha‑1 gave lower IL-17 than the other groups.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-17, combination of CsA and Talpha1
    Study

    mousen: not reported in source

    BALB/c mice
    Comparator
    Other groups
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Compared with other groups, CsA+Talpha1 group had significant lower IL-1alpha, IL-2, IL-6, IL-17, and significant higher IL-10 at 1 d, 7 d, 14 d, 21 d after the treatments (P < 0.05).
    3 context sentences
    Summary · context
    Sixty five BABL/c mice were divided into four groups: CsA group (n=20), Talpha1 group (n= 20), CsA+Talpha1 group (n=20) and control group (n=5).
    Summary · context
    25 mg/mL CsA, 10 microg/mL Talpha1 or 0.25 mg/mL CsA+10 microg/mL Talpha1 in vitro, respectively.
    Summary · context
    Three days later, OD values of each treated lymphocyte culture and several cytokines in the culture were measured.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 06AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice, the combination of CsA and Talpha1 gave higher IL-10 than the other groups at 1, 7, 14 and 21 days.

    In plain wordsIn mice, cyclosporin A plus thymosin alpha‑1 gave higher IL-10 than the other groups.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-10, combination of CsA and Talpha1
    Study

    mousen: not reported in source

    BALB/c mice
    Comparator
    Other groups
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Compared with other groups, CsA+Talpha1 group had significant lower IL-1alpha, IL-2, IL-6, IL-17, and significant higher IL-10 at 1 d, 7 d, 14 d, 21 d after the treatments (P < 0.05).
    3 context sentences
    Summary · context
    Sixty five BABL/c mice were divided into four groups: CsA group (n=20), Talpha1 group (n= 20), CsA+Talpha1 group (n=20) and control group (n=5).
    Summary · context
    25 mg/mL CsA, 10 microg/mL Talpha1 or 0.25 mg/mL CsA+10 microg/mL Talpha1 in vitro, respectively.
    Summary · context
    Three days later, OD values of each treated lymphocyte culture and several cytokines in the culture were measured.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 07LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Efficacy outcome

    In cultured mouse spleen lymphocytes, IL-1alpha was lower in the pooled experimental groups (Talpha1, CsA and combination) than in the control.

    In plain wordsIn cells from mouse spleen, IL-1alpha was lower in the treated groups, which pooled thymosin alpha‑1, cyclosporin A and both, than in controls.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-1alpha in lymphocyte culture, experimental groups
    Study

    mousen: not reported in source

    mouse spleen lymphocyte culture
    Comparator
    Control
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    IL-1alpa and IL-6 in the control group were significantly higher than those in the experiment groups (P < 0.05), while IL-10 in the control group was significantly lower than that in the experiment groups (P < 0.05).
    3 context sentences
    Summary · context
    Sixty five BABL/c mice were divided into four groups: CsA group (n=20), Talpha1 group (n= 20), CsA+Talpha1 group (n=20) and control group (n=5).
    Summary · context
    25 mg/mL CsA, 10 microg/mL Talpha1 or 0.25 mg/mL CsA+10 microg/mL Talpha1 in vitro, respectively.
    Summary · context
    Three days later, OD values of each treated lymphocyte culture and several cytokines in the culture were measured.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 08LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Efficacy outcome

    In cultured mouse spleen lymphocytes, IL-6 was lower in the pooled experimental groups (Talpha1, CsA and combination) than in the control.

    In plain wordsIn cells from mouse spleen, IL-6 was lower in the treated groups, which pooled thymosin alpha‑1, cyclosporin A and both, than in controls.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-6 in lymphocyte culture, experimental groups
    Study

    mousen: not reported in source

    mouse spleen lymphocyte culture
    Comparator
    Control
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    IL-1alpa and IL-6 in the control group were significantly higher than those in the experiment groups (P < 0.05), while IL-10 in the control group was significantly lower than that in the experiment groups (P < 0.05).
    3 context sentences
    Summary · context
    Sixty five BABL/c mice were divided into four groups: CsA group (n=20), Talpha1 group (n= 20), CsA+Talpha1 group (n=20) and control group (n=5).
    Summary · context
    25 mg/mL CsA, 10 microg/mL Talpha1 or 0.25 mg/mL CsA+10 microg/mL Talpha1 in vitro, respectively.
    Summary · context
    Three days later, OD values of each treated lymphocyte culture and several cytokines in the culture were measured.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  8. 09LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Efficacy outcome

    In cultured mouse spleen lymphocytes, IL-10 was higher in the pooled experimental groups (Talpha1, CsA and combination) than in the control.

    In plain wordsIn cells from mouse spleen, IL-10 was higher in the treated groups, which pooled thymosin alpha‑1, cyclosporin A and both, than in controls.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-10 in lymphocyte culture, experimental groups
    Study

    mousen: not reported in source

    mouse spleen lymphocyte culture
    Comparator
    Control
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    IL-1alpa and IL-6 in the control group were significantly higher than those in the experiment groups (P < 0.05), while IL-10 in the control group was significantly lower than that in the experiment groups (P < 0.05).
    3 context sentences
    Summary · context
    Sixty five BABL/c mice were divided into four groups: CsA group (n=20), Talpha1 group (n= 20), CsA+Talpha1 group (n=20) and control group (n=5).
    Summary · context
    25 mg/mL CsA, 10 microg/mL Talpha1 or 0.25 mg/mL CsA+10 microg/mL Talpha1 in vitro, respectively.
    Summary · context
    Three days later, OD values of each treated lymphocyte culture and several cytokines in the culture were measured.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  9. 10LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Efficacy outcome

    In cultured mouse spleen lymphocytes, IL-2 was similar in the pooled experimental groups and the control.

    In plain wordsIn cells from mouse spleen, IL-2 was similar in treated groups and controls.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeIL-2 in lymphocyte culture, experimental groups
    Study

    mousen: not reported in source

    mouse spleen lymphocyte culture
    Comparator
    Control
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    IL-2 and IL-17 were similar.
    3 context sentences
    Summary · context
    Sixty five BABL/c mice were divided into four groups: CsA group (n=20), Talpha1 group (n= 20), CsA+Talpha1 group (n=20) and control group (n=5).
    Summary · context
    25 mg/mL CsA, 10 microg/mL Talpha1 or 0.25 mg/mL CsA+10 microg/mL Talpha1 in vitro, respectively.
    Summary · context
    Three days later, OD values of each treated lymphocyte culture and several cytokines in the culture were measured.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  10. 11LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Efficacy outcome

    In cultured mouse spleen lymphocytes, IL-17 was similar in the pooled experimental groups and the control.

    In plain wordsIn cells from mouse spleen, IL-17 was similar in treated groups and controls.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeIL-17 in lymphocyte culture, experimental groups
    Study

    mousen: not reported in source

    mouse spleen lymphocyte culture
    Comparator
    Control
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    IL-2 and IL-17 were similar.
    3 context sentences
    Summary · context
    Sixty five BABL/c mice were divided into four groups: CsA group (n=20), Talpha1 group (n= 20), CsA+Talpha1 group (n=20) and control group (n=5).
    Summary · context
    25 mg/mL CsA, 10 microg/mL Talpha1 or 0.25 mg/mL CsA+10 microg/mL Talpha1 in vitro, respectively.
    Summary · context
    Three days later, OD values of each treated lymphocyte culture and several cytokines in the culture were measured.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.